The Alzheimer’s disease diagnostics and therapeutics market was valued at USD 6,986.70 million in 2021, and it is expected to reach USD 9,639.23 million by 2027, registering a CAGR of 5.51% during the forecast period.
The emergence of the COVID-19 pandemic had its impact on the studied market of Alzheimer’s disease diagnostics and therapeutics market as both diagnostics and therapeutics procedures around the world were impacted owing to the decline in the visits to the hospitals and diagnostic centers because of the lockdown restriction imposed by various governments, globally. Further, many studies reported the negative impact of the COVID-19 on Alzheimer’s patients which is also expected to have an impact on the studied market. For instance, as per the study titled, "Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes, a UK Biobank study", published in November 2020, it was observed that patients suffering from dementia are at the highest risk of mortality from COVID-19. However, with the ongoing vaccinations and decreasing cases of COVID-19, the studied market is expected to regain its full potential over the forecast period.
The major factor driving the growth of the Alzheimer’s disease diagnostics and therapeutics market is the increasing use of the biomarkers in the Alzheimer’s diagnosis and drug development coupled with the rising prevalence of Alzheimer’s around the world. For instance, according to the September 2021 report of the World Health Organization, about 55 million people around the world are living with dementia and nearly 10 million cases are reported every year and as per the same source, Alzheimer’s is the most common form of dementia and constitute about 60-70% of the total cases of dementia. Further, with the growing prevalence of Alzheimer’s around the world, the government and non-government entities are investing heavily in the development of diagnostics and therapeutics for Alzheimer’s which will further augment the growth of the studied market. For instance, in June 2021, the Alzheimer’s Drug Discovery Foundation (ADDF) Diagnostics Accelerator launched four new research investments for development of digital biomarkers for Alzheimer's diagnosis, and thus, investment like this is further expected to propel the growth in the studied market.
Additionally, with the advancement in the diagnostic technologies and ongoing research activities in the area, the companies are enhancing their product offering and launching new products and coupled with other business expansion initiatives like mergers and acquisitions, strategic collaboration and new investments into other companies are also expected to compliment the growth of the Alzheimer’s disease diagnostics and therapeutics market over the forecast period. For instance, in August 2019, a company called Oxford Brain Diagnostics (a spinout from Oxford University) was launched to deliver a new method for diagnosing Alzheimer’s Disease from MRI scans. However, high failure rates of clinical studies related to diagnosis and treatment and challenges in early diagnostics of Alzheimer's are expected to impede the growth of the Alzheimer’s disease diagnostics and therapeutics market over the forecast period.
Key Market Trends
Cholinesterase Inhibitors are Expected to Hold the Highest Market Share in the Therapeutics Segment
Cholinesterase inhibitors are also known as acetylcholinesterase inhibitors and are a class of therapeutics that stop the normal breakdown of acetylcholine which is a neurotransmitter. The cholinesterase inhibitors shut off the action of the enzyme cholinesterase, which is responsible for breaking down acetylcholine neurotransmitters in the body. As the cholinesterase inhibitors are found to be slightly delaying the loss of brain function in people suffering from mild to moderate Alzheimer’s disease, they are widely prescribed to treat symptoms related to memory, thinking, language, judgment, and other thought processes. Currently, the major cholinesterase inhibitors drugs that are available in the market and widely used are donepezil, galantamine, rivastigmine, and memantine in the treatment of Alzheimer’s disease.
In the market, currently, cholinesterase inhibitors are the major drugs that are available for Alzheimer’s because the enzyme cholinesterase is a significant therapeutic target for Alzheimer's which is why the studied segment is expected to grow over the forecast period as a number of pharmaceutical companies are focused towards developing Alzheimer’s therapeutics based on cholinesterase inhibitors. For instance, in October 2021, Corium, Inc., received March 11, 2022, as date for Prescription Drug User Fee (PDUFA) target action from the United States Food and Drug Administration for its new drug application (NDA) for once-weekly ADLARITY (donepezil transdermal system) for the treatment of patients with Alzheimer's disease. Donepezil is the most prescribed medication in a class of Alzheimer's drugs known as cholinesterase inhibitors. Therefore, new developments like this are further expected to augment the growth of the studied segment.
Additionally, during the COVID-19 pandemic, cholinesterase is being studied extensively for its safety, efficacy, and side effects in Alzheimer's patients with COVID-19 infection which is further expected to have its impact on the growth of the studied segment as the cases of COVID-19 increasing around the world. For instance, as per the study, "Potential Novel Role of COVID-19 in Alzheimer’s Disease and Preventative Mitigation Strategies", published in June 2020, the cholinergic anti-inflammatory pathway was observed to be a viable target to control inflammation and for the prevention of cytokine storm post detection of COVID-19 virus infection in Alzheimer's patients, and acetylcholinesterase inhibitors can potentially be administered as an adjunctive therapy. Thus, COVID-19 is also expected to have its impact on the growth of the cholinesterase inhibitors segment over the forecast period.
North America Is Expected to Dominate the Alzheimer’s Disease Diagnostics and Therapeutics Market Over the Forecast Period
North America held a major share of the Alzheimer’s disease diagnostics and therapeutics market in the past few years and is expected to show a similar trend over the forecast period, primarily due to the high burden of Alzheimer’s disease coupled with the increasing aging population, huge investment in research and development activities and launch of new products in the region. For instance, in June 2021, in an interview, the Chief Science Officer of Alzheimer Society of Canada stated that “Over the next 10 years, we anticipate that more than one million people in Canada will be living with dementia”, which shows the increasing prevalence of Alzheimer’s in North America region that is expected to increase the demand of the diagnostics and therapeutics products for Alzheimer’s which will drive the growth in the studied market over the forecast period.
Also, the growing aging population in the region is also expected to increase the burden of Alzheimer’s disease in the region as the geriatric population is more prone to neurodegenerative diseases like Alzheimer’s as it is an age-associated disease. For instance, according to the World Population Ageing Highlight report of 2019 published by the United Nation, in 2019, the geriatric (aged 65 years and more) population of United States was 53,340,00; 6,602,000 in Canada, and 9,462,000 in Mexico and by 2050, it is projected to increase to 26,416,000 in Mexico, 11,436,000 in Canada, and 84,813,000 in the United States.
In North America, the United States is expected to hold a major market share during the forecast period in the studied market due to the high prevalence of Alzheimer’s diseases, new product launches growing geriatric population and presence of robust healthcare infrastructure for Alzheimer’s diagnostics and treatment. For instance, according to the March 2021 report of the Alzheimer’s Association, approximately 6.2 million people of age 65 years and more are living with Alzheimer’s related dementia in the United States, and it is projected that this number will increase to 13.8 people by 2060. Further, as per the same source, Alzheimer’s and dementia related deaths in the United States have increased by 16% during the COVID-19 pandemic and it was estimated that in 2021, Alzheimer’s and other dementia incurred cost of about USD 355 billion on the country and it is expected that by 2050, this cost could rise to more than USD 1.1 trillion. These data from the Alzheimer’s Association not just shows the high prevalence of Alzheimer’s diseases in the United States but also the financial burden on the country’s economy due to it and therefore, the demand of diagnostics and treatment for Alzheimer’s is expected to increase significantly in the country that will boost the growth in the studied market of Alzheimer’s disease diagnostics and therapeutics.
Furthermore, the increasing number of research studies related to the diagnosis and management of Alzheimer's disease and high investment in the country over Alzheimer’s by the government as well as private entities, the studied market of Alzheimer’s disease diagnostics and therapeutics if further expected to grow in the United States over the forecast period. For instance, in December 2020 , the United States Congress USD 300 million increase for Alzheimer’s and dementia research funding at the National Institutes of Health (NIH), including USD 15 million to fund and implement the Building Our Largest Dementia (BOLD) Infrastructure for Alzheimer’s Act, and advances the Improving HOPE for Alzheimer’s Act for FY 2021. Therefore, due to these above-mentioned factors, the Alzheimer’s disease diagnostics and therapeutics market is expected to grow during the forecast period in the region.
The Alzheimer’s disease diagnostics and therapeutics market is moderately competitive and consists of several major players. With technological advancements and product innovation, mid-size to smaller companies are expanding their market presence by introducing new technologies with better results. Companies like F. Hoffmann-La Roche, Eli Lily and Company, Eisai Co. Ltd., Siemens Healthineers, and Abbvie Inc. among others are some of the major players in the studied market.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Use of Biomarkers in Diagnosis and Drug Development
4.2.2 Large Number of Drugs in Pipeline
4.2.3 Emerging Novel Diagnostic Technologies
4.3 Market Restraints
4.3.1 High Failure Rates of Late-stage Drugs
4.3.2 Lack of Surrogate Markers and Challenges in Early Diagnosis
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
126.96.36.199 Cholinesterase Inhibitors
188.8.131.52 NMDA Receptor Antagonists
184.108.40.206 Other Therapeutics
220.127.116.11 Brain Imaging
18.104.22.168 CFS Test for Alzheimer's Disease
5.2.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle-East and Africa
5.2.5 South America
126.96.36.199 Rest of South America
6.1.1 F. Hoffmann-La Roche
6.1.2 Bristol-Myers Squibb
6.1.3 AstraZeneca Plc
6.1.4 Corium Inc.
6.1.5 Eisai Co. Ltd
6.1.6 Biogen Inc.
6.1.7 Johnson & Johnson
6.1.8 Eli Lilly and Company
6.1.9 Lupin Limited
6.1.10 Abbvie Inc
6.1.11 Siemens Healthineers
6.1.12 Zydus Cadila
6.1.13 Merz Pharma
6.1.14 Teva Pharmaceutical Industries Ltd
6.1.15 Adamas Pharmaceuticals Inc.
A selection of companies mentioned in this report includes:
- F. Hoffmann-La Roche
- Bristol-Myers Squibb
- AstraZeneca Plc
- Corium Inc.
- Eisai Co. Ltd
- Biogen Inc.
- Johnson & Johnson
- Eli Lilly and Company
- Lupin Limited
- Abbvie Inc
- Siemens Healthineers
- Zydus Cadila
- Merz Pharma
- Teva Pharmaceutical Industries Ltd
- Adamas Pharmaceuticals Inc.